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MICROBICIDES: A GLOBAL PRIORITY
Background
The HIV/AIDS epidemic continues to spread, undermining
development, reversing health gains, and exacerbating pover-
ty. Over 36 million people worldwide are living with
HIV/AIDS and 95% of them are in developing countries.
Every day more than 16,000 people are newly infected with
HIV and current prevention strategies are inadequate to stop
the rapid spread of the epidemic. It is estimated that there
have been 21.8 million AIDS-related deaths through the end
of 2000. Although research on a preventive vaccine is critical-
ly important and moving forward, it will be some time before
a vaccine is available and accessible. There is an urgent need
to identify additional prevention options. 
Women are increasingly affected by HIV/AIDS, repre-
senting 47% of those infected globally and more than 55% of
those infected in sub-Saharan Africa, 30% in Asia, and 20%
in Europe and the USA. In 2000, almost 5 million adults were
newly infected with HIV, of whom nearly half were women.
More than 90% of new infections are spread through unpro-
tected sex, and women, especially young women, are biologi-
cally more vulnerable to HIV and other sexually transmitted
infections (STIs) than men. Because of gender inequality, con-
doms, while effective if used correctly and consistently, are
simply not a feasible option for many women. The develop-
ment of a prevention method that women control could save
millions of lives. 
A microbicide—a product used vaginally to prevent
infection—would offer the potential for women to protect
themselves and their sexual partners from HIV and other STIs.
The prospects for developing microbicides are promising.
There is growing consensus that developing a microbicide
should be technically feasible, and there has been significant
progress in microbicide research and development over the
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last ten years. A number of promising new products are in the
pipeline, and findings from market and acceptability research
are encouraging. Attention from public-sector and nonprofit
agencies and some pharmaceutical companies is increasing,
and women in developed and developing countries have
expressed high levels of interest in these products.
Most current microbicide research and development is car-
ried out by small biotechnology firms, nongovernmental organ-
isations, and academic institutions, largely supported by public
funding. No major pharmaceutical company has made a signifi-
cant investment in microbicide research and development.
Neither the public nor the private sector is investing sufficient
resources in microbicide research and development and, at pres-
ent rates of progress, it is likely to be another decade before safe,
effective, and affordable microbicides are available. Reducing
this timeframe will require a major increase in investment from
a variety of sources, as well as global political commitment, a
focused product-oriented strategy, and continued collaboration
between scientists, researchers, the public sector, donors, indus-
try, and advocates in developed and developing countries. 
This document presents the case for microbicides, 
discusses recent progress and developments, and notes out-
standing challenges and the action required to accelerate
research and development and to ensure that products will be
made available to those who most need them. 
The need for female-controlled methods
The HIV/AIDS epidemic is driven by social, cultural, and eco-
nomic gender inequalities that limit women’s ability to protect
themselves from infection. The main strategies for HIV pre-
vention—condoms, reducing the number of sexual partners,
and treatment of reproductive tract infections—are not feasi-
ble for many women. 
Condom use depends on the consent of male sexual
partners and it can be difficult for women to raise the subject
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in relationships where men make sexual decisions and
women are economically dependent. Discussing condom use
or refusing unsafe sex is particularly difficult in the context of
primary partnerships and where women are subject to 
violence. The female condom has been a good option for
some women, but it is not widely available. Reproductive
health programmes should make every effort to expand
access to and use of the female condom while continuing to
build support for the development and rapid introduction 
of microbicides. Because they are also contraceptives, con-
doms can be especially problematic where proving fertility is 
critical to women’s status or for couples who wish to 
have children. 
Reducing the number of sexual partners may not be fea-
sible for those women who, because of limited educational
and employment opportunities, have few alternatives to
exchanging sex for economic survival. In many regions a sig-
nificant proportion of women are infected with HIV by their
husbands. Even when women themselves are monogamous,
their partners may not be.
Sexually transmitted infections in women are often
asymptomatic, making women less likely to seek treatment,
and syndromic management of STIs is less precise in women
than in men. The laboratory facilities required to accurately
diagnose STIs are also not available in many settings. Even
women who do have symptoms of STIs may avoid seeking
treatment for fear of stigmatisation. Therefore, many STIs go
untreated in women, often with severe health consequences,
including increased risk of HIV infection.
Given the limitations of these existing approaches, there
is an urgent need to extend the range of prevention methods
available, particularly those that women can control. New
products, such as microbicides, have the potential to strength-
en HIV prevention efforts by allowing women, men, and cou-
ples to choose from, and use, a wider range of methods. 
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The potential of microbicides
To be truly female controlled, the ideal microbicide would be
effective, safe, acceptable, affordable, colourless, odourless, sta-
ble, easy to store and use, available in a variety of preparations,
available in contraceptive and noncontraceptive formulations,
and available without a prescription. However, because the
first microbicide to be developed is unlikely to be an “ideal”
product with all these characteristics, the immediate priority is
to develop a microbicide that provides protection if used con-
sistently and that will be used by those who need it most.
A microbicide would potentially be effective against a
range of STIs in addition to HIV. Unlike condoms, it could be
applied in advance of sexual activity and perhaps without
requiring the active involvement of sexual partners.
Microbicides could increase protection when used in addition
to condoms, and could provide a back-up in cases of condom
failure. Because consistency of use and coverage is as impor-
tant as efficacy in determining impact, even a partially effec-
tive product could have a significant impact on HIV transmis-
sion for individuals and societies where condom use is low.
Used rectally, microbicides could also potentially reduce the
risk of HIV transmission via anal sex.
While microbicides will have the greatest impact in the
developing world in countries most affected by HIV and other
STIs, there is also an important potential role for microbicides
in reducing STIs in developed countries. As noted earlier,
women represent 20% of people infected with HIV in Europe
and the USA. In addition, there is a potentially large and
lucrative market for microbicides among men who have sex
with men and among women at risk of other STIs, such as
chlamydia.
In many cultures and for many couples the importance of
having children is a major obstacle to condom use and could
also limit use of contraceptive microbicides. Women currently
have no option that allows them to conceive while protecting
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them from disease. Therefore, an urgent need exists for non-
contraceptive as well as contraceptive formulations. 
Microbicides could help protect children and men, as well
as women. By reducing the risk of HIV infection in women,
microbicides would contribute to a reduction in mother-to-
child transmission of HIV. In addition, some microbicides may
have the potential to reduce mother-to-child transmission
when used for vaginal washing in HIV-positive women prior
to delivery. Ideally, microbicides would prevent HIV transmis-
sion from women to men and could, therefore, be critical for
women with HIV who are unable to disclose their status to
sexual partners and serve to protect HIV-negative men from
infection. They may also have the potential to protect HIV-
positive women from reinfection.
Microbicides offer many potential advantages for increas-
ing a woman’s control over her sexual life and for protecting
women, men, and children from infection. This potential is
moving closer to being realised through the growing efforts of
numerous scientists and advocates to develop a safe and effec-
tive product and make it available to those most at risk.
CURRENT STATUS AND 
RECENT DEVELOPMENTS
Approaches to microbicide development
Scientists have taken two general approaches to microbicide
development: developing and testing new substances, and
investigating the potential microbicidal activity of existing
spermicidal products.* These approaches focus on microbicide
products that act in one of the following ways or that combine
different mechanisms in one product:
• Killing or inactivating infectious pathogens—examples include
surfactants (detergent-like chemicals) that disrupt the lipid
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* Mention of specific products in development does not constitute endorsement.
membranes of cells and the lipid envelopes (surfaces) of
viruses such as HIV and herpes, and certain antibiotics that
increase membrane porosity. The surfactants include the
existing spermicides nonoxynol-9, octoxynol-9, benzalkonium
chloride, menfegol, and novel substances that work in a sim-
ilar way. 
• Blocking attachment to target cells and entry of infectious
pathogens—these compounds may prevent infection by block-
ing the attachment of pathogens to the mucosal surface of tar-
get cells. Examples include sulphated and sulphonated poly-
mers such as Carraguard™, PRO 2000, and Emmelle. 
• Preventing infection from taking hold—examples include anti-
retroviral agents like PMPA gel, which prevents HIV from
replicating in cells, and plantibodies, anti-HIV antibodies
genetically engineered from plants that would combat
pathogens before infection occurs.
• Enhancing vaginal defence mechanisms—this approach seeks
to enhance the vagina’s naturally acidic environment and
production of hydrogen peroxide, both of which are hos-
tile to pathogens including HIV. Examples include BufferGel™
and Acidform, which help the vagina to maintain natural
levels of acidity in the presence of semen, and supposito-
ries containing lactobacillus, which lives normally in the
healthy vagina and which produces hydrogen peroxide. 
Recent progress in microbicide research
and product development
Microbicide research is increasingly considered a legitimate sci-
entific field. Basic research is growing on issues critical to micro-
bicide development and testing, such as sexual transmission of
HIV and other pathogens, vaginal ecology, and appropriate in
vitro assays and animal models. The prospects for product
development are encouraging and the number of researchers
and approaches is growing. Five years ago, only a handful of
6
researchers were working on microbicides. Today, according to
the Alliance for Microbicide Development, which monitors
product research and development, 38 small biopharmaceutical
companies, 28 nonprofit research entities, and six public-sector
agencies are working on microbicides. In 1994, a dozen com-
pounds were in the preclinical stages of development, with just
eight ready for early Phase I safety trials and none ready for
later trials of product efficacy. In contrast, in 2000 over 50 prod-
uct leads are in development, of which seven are in later-stage
clinical trials. Despite this progress in expanding the number of
products being developed, they are not moving into expanded
clinical testing quickly enough; almost three dozen potential
products remain in some stage of preclinical testing. 
7
PRECLINICAL STUDIES—labo-
ratory and animal studies to
assess potential effectiveness
against HIV, other STIs, and
sperm; toxicity; compatibility with
barrier methods; and to predict
dosages required, before moving
to clinical studies. 
CLINICAL STUDIES—to assess
safety and effectiveness in
humans. Generally have been
divided into three phases. Phase I
trials are conducted in small num-
bers (10–50) of women at low risk
of sexually transmitted infection, to
assess initial safety and accept-
ability. Phase II trials enroll larger
numbers of women—several hun-
dred—potentially at risk of HIV
and other STIs, and women with
HIV, to further assess safety and
acceptability and to provide prelim-
inary information about efficacy.
Phase III trials are conducted in
larger numbers—typically hun-
dreds to thousands—of women at
risk of HIV and other STIs, to pro-
vide information about safety of
longer-term use and effective-
ness—whether or not the product
reduces HIV and other STIs. Given
the urgency of the epidemic and
the timeframe required for clinical
testing, there is growing discus-
sion and exploration of ways to
streamline this process through,
for example, conducting various
safety tests simultaneously, con-
ducting multi-armed studies, and
ensuring that data from Phase II
and III trials can be pooled.  
ESTABLISHING MICROBICIDE 
SAFETY AND EFFECTIVENESS
8• A successful trial with BufferGel™
(produced by Reprotect LLC) was
conducted through HIVNET (now
the Prevention Trials Network/
HPTN) in four sites in India,
Malawi, Thailand, and Zimbabwe.
HPTN is also conducting Phase I
trials of PRO 2000 (Interneuron)
in sexually active HIV-positive
and HIV-negative women in two
South African and two US sites. 
• WHO is planning to collaborate
with CONRAD and TOPCAD on a
Phase II clinical trial of cellu-
lose sulphate gel, following a
successful Phase I trial.
• The UK Medical Research Council
and the Institute of Tropical
Medicine in Antwerp conducted
Phase I trials with PRO 2000
(Interneuron) and Emmelle (ML
Laboratories) in London and
Antwerp. Data so far show that
both products are well tolerated
and free of significant side
effects in women, and there is
evidence of protection in
macaques. The London and
Antwerp teams will jointly mount
Phase II trials with these sub-
stances in Ivory Coast and
Uganda during 2001.
• The Population Council is 
conducting a Phase II trial in
South Africa and Thailand with
Carraguard™, a carrageenan
gel, to further assess safety and
acceptability; if Carraguard is
found to be safe, a Phase III 
trial will start in early 2002.  
• Several Phase III trials with 
the spermicidal surfactant
nonoxynol-9 have so far failed to
show any benefit in terms of 
preventing transmission of 
HIV, gonorrhoea, or chlamydia in
female sex workers. These
include a trial of a vaginal con-
traceptive film (70mg nonoxynol-
9) carried out by Family Health
International in Cameroon, and a
trial of a gel formulation of
nonoxynol-9 known as COL-1492
(52.5mg nonoxynol-9) sponsored
by UNAIDS and carried out in
Benin, Ivory Coast, South Africa,
and Thailand. The data from the
four-country trial are still under-
going analysis and the basis of
its disappointing outcome is not
yet clear. When the data are fully
analysed, WHO will convene a
consensus meeting to determine
future policy recommendations
about use of n-9.  
MICROBICIDE CLINICAL TRIALS
Acceptability and demand
Laboratory and clinical research has been complemented by a
growing body of research and literature related to user per-
spectives on microbicides. Overall, the findings of this research
on acceptability, consumer interest, and potential markets for
such products are encouraging, suggesting that there is likely
to be demand in both developing and developed countries.
Acceptability studies in a range of countries, including
Brazil, India, South Africa, Thailand, Uganda, the US, and
Zimbabwe, have confirmed the urgent need women feel for 
a prevention method they control. In these studies women 
have expressed generally very positive attitudes towards the
concept and use of microbicide products in both contraceptive
and noncontraceptive formulations. With respect to formula-
tion, although women express preferences for different char-
acteristics and types of microbicide products, proven safety and
effectiveness against HIV and other STIs are generally the most
important considerations. Initial studies of men in varied set-
tings in Mexico, USA, and Zimbabwe found that they were also
generally supportive of the idea of microbicides.
A market survey in the USA, conducted by the Alan
Guttmacher Institute, estimated that 12.6 million American
women would be “interested” in using a microbicidal product
and approximately 7.7 million would be “very interested,”
even at a cost roughly twice that of a male condom. Another
market study, conducted by Hillmark Consulting among
urban women in 11 countries—Brazil, Egypt, France, India,
Ivory Coast, Kenya, Philippines, Poland, South Africa,
Thailand, and Venezuela—concluded that there is potentially
a substantial commercial market for microbicides that is suffi-
cient to justify further product development. 
Growing interest in microbicides
Scientific and policy interest in microbicides has grown steadi-
ly, evidenced by some of the following key developments:
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• The International Working Group on Microbicides
(IWGM), established in 1994, is comprised of major public
agencies involved in microbicide funding, research, and
development. It aims to facilitate the development, pro-
duction, and distribution of microbicides, promotes sharing
of research information, and provides technical expertise
for the development of research guidelines.
• A 1997 symposium on Practical and Ethical Dilemmas in the
Clinical Testing of Microbicides, cosponsored by the
Population Council and Women’s Health Advocates on
Microbicides, brought together 55 scientists, activists, and
ethicists from 15 countries to debate and build consensus
on how to conduct microbicide clinical trials.
• The Alliance for Microbicide Development, a consortium of
biopharmaceutical companies, research organisations, and
advocacy groups, was founded in 1998. It catalyses diverse
interests at work in the field, educates policymakers and
the public, advocates for microbicide development, tracks
and communicates progress, and aims to reduce disincen-
tives and stimulate investment in microbicide research and
development.
• An October 1998 meeting, organised by Family Health
International, IWGM, the Consortium for Industrial
Collaboration in Contraceptive Research, and CONRAD,
reviewed opportunities for collaboration between industry
and the public sector. 
• A Global Campaign for Prevention Options for Women
was launched in 1998 to increase public awareness,
mobilise political will, and increase investment by the
public sector and private donors. It now has more than 
60 cosponsors worldwide with a secretariat at PATH 
(e-mail: globalcampaign@path-dc.org).
• In 1999, 2000, and 2001, Preclinical Evaluation
Workshops, sponsored by the National Institute of Allergy
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and Infectious Diseases, National Institutes of Health
(NIH), assessed scientific progress and outstanding ques-
tions related to laboratory testing of microbicides. 
• The first major international scientific conference,
Microbicides 2000, held in March 2000 in Washington,
DC, was attended by more than 650 participants from 
40 countries. 
While investment remains insufficient, there have
recently been some encouraging steps forward in funding for
microbicide research and development: 
• The European Commission has increased funding for 
scientific and policy research, and in 2000 identified micro-
bicides as a priority in its HIV/AIDS programme in devel-
oping countries, joining other European funders such as
the Department for International Development (DfID) and
the Swedish International Development Agency (SIDA). 
• The National AIDS Research Institute in France recently
established a microbicides working group, is funding a
number of studies, and has expressed interest in increasing
support for microbicide research and development. 
• The Microbicides Development Act, under consideration
by the US Congress, proposes a progressive increase in NIH
investment in microbicides research and development
from its current level of approximately $23 million to
reach $100 million in 2003.
• Private funding in the USA has also increased in response to
advocacy. For example, in 2000 the Gates Foundation pro-
vided a grant of $25 million for product development and
clinical trials, and in 1999 the American Foundation for AIDS
Research launched a grant initiative to support innovative
biomedical research on microbicides, joining other private
foundations such as Rockefeller, Mellon, and Hewlett in sup-
porting microbicides research. In 2001 the Ford Foundation
committed $1 million and the Goldman Foundation
$500,000 to support advocacy activities. There has also been
initial interest and investment by venture capitalists. 
CHALLENGES TO BE ADDRESSED
Building on recent advances to make a product available 
will require a significant increase in investment from both 
the public and private sectors to accelerate research and
development. A major increase in funds should be accompa-
nied by a strategic plan and clear criteria for how to best 
target these resources to advance the most promising prod-
ucts and overcome bottlenecks in the research and develop-
ment process. Devising strategies to increase public support
and to address barriers to industry involvement is crucial.
Finally, it is critical to step up planning efforts to ensure
future product availability and access. 
Increasing public-sector investment
Because of the near absence of private-sector support from
the pharmaceutical industry, the advances achieved in micro-
bicide research and development have derived almost 
exclusively from public-sector investment. A number of gov-
ernment and intergovernmental agencies have supported
microbicide work to varying degrees, including the European
Union, UNAIDS (including funds from the governments of
Germany and Belgium), WHO, national agencies such as 
the UK Medical Research Council, and bilateral donors such
as SIDA and the UK DfID. It is estimated that the US public
sector invested around $32 million in 1999 (NIH $26 million,
CDC $4 million, USAID $2.3 million) in microbicide-related
research. Globally the public sector provided less than 
$40 million for microbicide research during 1999. 
While this investment has been crucial, microbicides
remain low on the agendas of most international and govern-
mental funding bodies, and current levels of public investment
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are insufficient for the work that needs to be done. Among the
urgent requirements are advancing the most promising prod-
ucts into and through the large-scale clinical trials needed to
demonstrate effectiveness against HIV and other STIs, and sup-
porting additional preclinical work on new leads. The Alliance
for Microbicide Development projects that an investment of
$100 million a year is required over the next five years to move
this work forward. Although this represents substantial fund-
ing, it is relatively little compared with overall spending on
AIDS research. For example, the US National Institutes of
Health spent $1.8 billion on AIDS research in 1999. 
Attracting private-sector investment 
To date, no major pharmaceutical company has made a signif-
icant investment in microbicide research and development
(R&D); it is estimated that investment by the pharmaceutical
industry is less than $3 million. The UK Medical Research
Council conducted an industry survey in 1995 in which none
of the companies surveyed expressed interest in investing in
microbicide research and development. The barriers cited
included scientific uncertainty about the concept; perceptions
of limited market and profit potential; competing demands for
R&D resources; regulatory uncertainty; and concerns about
safety and legal liability. A 1999 survey indicates that in the
intervening years industry attitudes towards microbicides have
generally become more positive, in response to developments
in research and efforts to improve market information. In 1999,
four of 30 companies surveyed expressed an interest in invest-
ing in research and development. The most critical barrier
remains a lack of clear evidence about effectiveness—proof of
the overall concept that a vaginal microbicide can prevent HIV
and other STIs, as well as the efficacy of specific substances. An
immediate priority must therefore be to conduct large-scale
clinical trials of products to provide proof of concept, while at
the same time working to address other industry concerns. 
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Markets and profitability
Perceptions about potential markets and profitability are a
significant barrier to private-sector investment in microbi-
cides. Industry has generally assumed that the profitability of
microbicides would be limited because the main market
would be in developing countries, that women in these
resource-poor settings would have limited willingness and
ability to pay, and that there would be considerable pressure
to distribute microbicides inexpensively. However, findings
from the two major market studies conducted to date suggest
that the developed-country market could be substantial and
that women in low-income countries would be willing to pay
for microbicides. 
The aforementioned AGI survey concluded that there are
potentially 7.7 million women in the US who would be “very
interested” in a microbicide at a cost roughly twice that of a
male condom. Even if the product were not 100% effective,
the number of women “very interested” would still be around
4 million. In the EC market study, 25% of urban women sur-
veyed in France thought a microbicide would be “very use-
ful.” The EC study also showed that women in developing
countries would be prepared to pay a relatively high price to
protect themselves from infection, especially when they think
they are at high risk of acquiring HIV and other STIs. More
than 60% of women surveyed in Ivory Coast and Kenya
expressed willingness to pay up to five times the price of a
male condom. The potential value of the market in urban
Kenya for a microbicide that costs twice the price of a condom
was estimated at $3.8 million a year. In Brazil, potential annu-
al sales could be worth $800 million. 
Regulatory concerns
Because microbicides represent a new product category, there
is no clear precedent for establishing regulatory requirements
for products at different stages of research and development,
determining what level of effectiveness would be required for
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approval and introduction, and establishing what data are
needed to support an application for product licensing. A
related issue is uncertainty about prescribing and labelling
information and possible caveats (for example, about use with
condoms), which could have significant implications for prod-
uct marketing and pricing. 
These issues have been recognised and some steps are
being taken towards resolving them. For example, the US
Food and Drug Administration has established a Topical
Microbicide Working Group that has made a commitment to
priority review of products to prevent serious and life-threat-
ening diseases, including microbicides for HIV prevention. The
working group is also committed to advising applicants about
the regulatory process, working to clarify preclinical require-
ments, and devising other fast-track mechanisms. These
mechanisms and approaches are still new and their effective-
ness in helping to bring a product to market has not been con-
firmed. However, a similar approach could be explored with
regulatory agencies in Europe, using the centralised applica-
tion procedure for European Union states of the European
Medicines Evaluation Agency.
Pricing and subsidy
As with any new public health product category intended for
the global market, microbicides also raise issues of intellectual
property, pricing, and subsidy. It is critical to devise pricing
mechanisms and purchase agreements to ensure that new
products are available and affordable for the developing world
and the public sector where they are needed most, while pro-
tecting intellectual property. Recent experience with
HIV/AIDS vaccines demonstrates that innovative partnership
arrangements can help reconcile industry’s interest in profit
with consumers’ need for safe and affordable products. 
Liability
Some industry executives have also expressed concern over
potential risk of liability, including both litigation related to side
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effects and failure to protect against HIV and other STIs. While
it is unclear whether liability is of equal concern for all compa-
nies and all markets, the topic warrants further examination.
Challenges for ensuring availability,
access, and use
The acute need for microbicides in many developing countries
makes it critical to take action now to identify and address con-
straints to availability and access. Many of these constraints,
such as problems of cost, supply, logistics, distribution, quality
assurance, and consumer information, echo experience with
development and introduction of other drugs and technologies.
Depending on the active ingredient, some microbicides may be
restricted to prescription only until there is sufficient experience
of use. However, devising ways to improve access by making
microbicides available over the counter from the outset is essen-
tial if they are to have a significant impact on the HIV/AIDS epi-
demic. Ensuring access will include establishing and engaging
innovative distribution networks, as well as traditional health
service delivery points, pharmacies, and retail outlets. 
These products will also need to be made available at an
affordable price. International agencies and governments need to
devise funding and distribution mechanisms to facilitate govern-
ment procurement and subsidies. Pricing may also be influenced
by taxes and tariffs on imported pharmaceutical products. This
challenge could be addressed, in part, by building local manufac-
turing capacity, but the level of investment required and compa-
nies’ willingness to invest require further examination. 
Effective education strategies will be essential to ensure that
both the public and individual consumers understand the con-
cept and potential benefits of microbicides, their risks and limi-
tations—particularly if a product is only partially effective—and
their proper use. Regardless of the distribution channels, health
professionals are likely to be important opinion leaders and must
also be targeted for training and education about microbicides.
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There is considerable scope to learn from experience with exist-
ing prevention methods, other nonprescription products, and
social marketing approaches. In addition, a growing body of
research is beginning to examine ways to convey appropriate
messages specifically about microbicides and their use. 
Scientific and research challenges 
Scientific knowledge about issues related to microbicides is
developing rapidly but there are outstanding questions requir-
ing research in basic, clinical, and social science. Additional
resources are needed to accelerate ongoing work and to build
capacity to address these research challenges, outlined below. 
Critical issues in basic research include understanding
mechanisms of transmission of HIV and other STIs during sex-
ual intercourse, so that microbicide research can be targeted
more effectively; expanding capacity for preclinical analysis of
potential products; developing better animal models, includ-
ing standardised assay methods to compare the potential 
efficacy of various candidate microbicidal compounds; gener-
alising from efficacy in vitro and in animal models to clinical
testing; and improving understanding about bioadhesion,
retention, and distribution in the vagina, and about optimal
formulations and dosages. 
In clinical research the cost, complexity, and length of
Phase II and III trials are key constraints. It is important to
continue to explore new and innovative approaches to
streamlining trials while maintaining the highest ethical stan-
dards. Trial sites must be in areas of high HIV incidence where
there is a strong research infrastructure. This limits the num-
ber of potential sites and calls for efforts to identify and
strengthen the capacity available at additional study sites. To
meet ethical standards, participants must receive safer-sex
counselling, condoms, and STI treatment; the optimum mix
and approach to these services needs further exploration and
refinement, and clearer guidelines for standards of services
17
and care are needed. It is critical to use the limited resources
available to test the most promising products, and developing
criteria and a system to select products for testing is a priori-
ty, as is developing standardised outcomes for assessing safe-
ty and efficacy. More information is needed about the effect
of other intravaginal products on microbicide safety and effi-
cacy; the effect of microbicides on tests to diagnose STIs; the
potential benefits of microbicides combined with barrier
methods that protect the cervix; and possible side effects of
long-term use and of use during pregnancy. 
Behavioural research is needed to improve understanding
about the determinants of product use and user effectiveness and
to evaluate acceptability in parallel with product development.
Existing acceptability studies indicate that multiple formulations
are needed to meet women’s different needs and preferences.
Ongoing research related to product formulation and mode of
delivery should be expanded to ensure the best chance of devel-
oping a successful product. In anticipation of product introduc-
tion, research about how women and couples understand, nego-
tiate, and act on information regarding partial effectiveness and a
hierarchy of prevention choices needs to be expanded. 
Policy research is needed to establish the potential cost-
effectiveness and impact of microbicides in HIV prevention at
different levels of use and efficacy, and to determine the
potential impact of introducing microbicides on condom use.
Additional information on the size and characteristics of the
potential market is also critical to help stimulate investment
and determine appropriate approaches to product introduc-
tion and distribution. Information to donors is essential to
stimulate an expanded financial base for microbicide research. 
MOVING FORWARD: 
PRIORITIES FOR ACTION 
Despite the urgent need for microbicides and their scientific
and public health promise, microbicides are a classic example
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of a product that will not reach the market without public-sec-
tor support. It is clear that the private sector alone will not
take forward microbicide research and development and that
current levels of public investment, while growing, are insuf-
ficient to accelerate and see through the process of bringing a
product to market. 
Given the limited availability of financial resources and
limited number of clinical trial sites, it is critical that product
development and testing be conducted efficiently to produce
one or more products that are safe, effective, and available.
The major stakeholders in microbicide research and develop-
ment, including donors and scientists, need to collaborate to
develop a scientific strategic plan and an agreed-upon set of
criteria for determining which candidate products should be
given priority for advancement. Building on this strategy 
and on existing initiatives, an appropriate mechanism and sci-
entific review process are needed to raise and allocate greatly
increased funding to specifically target bottlenecks in the R&D
process. For some public-sector and foundation donors, this
will be critical to attracting or increasing their investment. 
At the same time, strategies are needed to promote inno-
vative public–private partnerships that encourage greater
industry investment in microbicide research and develop-
ment. Public–private partnerships have the potential to reduce
the cost and risk to both sectors, provided that there are
shared goals, a clear understanding of roles, and a balance
between meeting the private-sector objective of seeking prof-
itable venture and the public-sector goal of making affordable
microbicides available in poorer countries and communities. A
number of recent efforts, including the International AIDS
Vaccine Initiative, the Medicines for Malaria Fund, the Global
Alliance for TB Drug Development, and the Children’s Vaccine
Initiative, can provide valuable lessons. 
International organisations, donor agencies, and govern-
mental bodies can act as catalysts in three key areas: 
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Increasing public investment and scientific interest in microbicides
Increased and targeted public-sector investment is essential in
order to accelerate R&D, generate more interest in the scien-
tific community, and support the research necessary to pro-
vide industry with evidence of effectiveness. Specific action is
needed to:
• Increase awareness and commitment to microbicides with-
in the international financial and development communi-
ty, governments, and donor agencies, and encourage these
public funding bodies to increase investment in microbi-
cide research and development. This will require greatly
expanded advocacy and, specifically, evidence of potential
cost-effectiveness, analysis of current levels of funding and
of investment required to move forward, and streamlined
mechanisms to attract and disburse funds.
• Stimulate demand for increased investment in microbi-
cides from developing-country policymakers, and from
women’s health groups, HIV/AIDS organisations, people
living with HIV/AIDS, and potential consumers in devel-
oped and developing countries. 
• Generate more interest and legitimacy within the scien-
tific community and attract additional scientific talent 
to microbicide research and development, through
increased funding, mechanisms to promote scientific col-
laboration and information exchange, and fast-track
funding procedures.
• Generate additional and more flexible funding focused on
product development, to follow up product leads and
move promising candidates through large-scale clinical tri-
als. Develop agreed-upon criteria for determining how
available funding and trial sites should be prioritised. 
• Provide support for identifying and strengthening the
capacity of appropriate trial sites and building the neces-
sary infrastructure with developing-country partners. 
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• Encourage dialogue among public funding agencies,
research institutions, and the biotechnology and pharma-
ceutical industry. The Eurovac project, which brings
together research expertise and industry in Europe for vac-
cine development, offers a useful model. 
Stimulating industry investment in research and development 
Attracting industry investment in microbicide research and devel-
opment will require efforts to improve and share market informa-
tion, clarify regulatory requirements and create a more supportive
regulatory environment, and develop strategies to stimulate mar-
kets and reduce legal liability risks. Specific action is needed to:
• Accelerate clinical research to provide proof of concept—
evidence to convince industry that microbicides can be
effective against HIV and other STIs. 
• Increase industry awareness of microbicides, including 
setting the stage for future private-sector production, deliv-
ery, and marketing.
• Create fast-track mechanisms for streamlining research,
development, and commercialisation, including the use of
orphan drug regulation. 
• Provide information about potential markets in developing
and developed countries, by taking into account both pub-
lic and private demand.
• Explore new sources of investment, including venture cap-
ital concerns that specialise in pharmaceuticals.
• Establish public-sector mechanisms to provide incentives
for industry and support market development through, for
example, international market guarantees and bulk pro-
curement. The World Bank, among other public-sector
agencies, should take the lead in this area. 
• Create supportive environments that stimulate research.
For example, research on policy incentives led microbicide
and HIV vaccine advocates to collaborate on introduction
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of tax credit legislation, under deliberation in the US
Congress, to encourage companies, especially small com-
panies, to stay in the field, and to attract new companies.
• Promote collaboration among scientists, regulatory bodies,
industry, and researchers to define “acceptable” levels of
effectiveness, recognising that the perfect product will
never be available and that there will be successive gener-
ations of products.
• Develop internationally agreed-upon regulatory require-
ments for licensing different types of microbicide products
and, for example, specifying conditions for over-the-count-
er products. Develop partnerships between regulators and
associations representing industry, brokered by public agen-
cies, to address regulatory, licensing, and related issues. 
• Consider how existing mechanisms, such as Trade Related
aspects of Intellectual Property, can be used to protect
patents in developing countries, and draw on the experi-
ence of organisations such as the International AIDS
Vaccine Initiative, which has been able to secure patent
rights for developing-country applications for AIDS vaccine
registration through innovative partnership agreements. 
• Assess how existing mechanisms, such as medical injury
compensation funds, could be used to reduce the risk of
legal liability, a particular concern for companies likely to
seek a market in the USA. Review other potential strate-
gies for reducing the risk of litigation, including consumer
education and counselling, clear and accurate labelling
information, and postmarketing surveillance.
• Assess the likely costs and requirements of establishing
manufacturing capacity, as well as the potential for tech-
nology transfer and developing-country production.
Ensuring availability, access, and use
Promoting action to plan for availability and accessibility—in
particular, policy dialogue with decisionmakers—needs to 
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happen well in advance of a product’s being proven effective.
Specific action is required to: 
• Provide information to convince policymakers, in devel-
oped and developing countries, about the potential role of
microbicides in preventing HIV and other STIs. This will
include analysis of the potential cost-effectiveness and
public health impact of microbicides with a range of char-
acteristics, in a range of settings, and in comparison with
and in combination with other preventive interventions.
• Promote dialogue with decisionmakers in developing
countries and provide technical support to prepare nation-
al policy frameworks for microbicides introduction, pro-
motion, and delivery, through health systems and as over-
the-counter products.
• Consider potential strategies for promoting access and
affordability—for example, advocacy with appropriate
agencies to ensure microbicides are included in Essential
Drugs Lists, bulk procurement, subsidies, incentives, and
the potential of different financing mechanisms. 
• Increase the involvement of international, bilateral, and
technical agencies that could contribute to microbicide
availability, access, and affordability, based on their areas of
comparative advantage—for example, UNAIDS through its
global leadership on HIV/AIDS, UNFPA through its man-
date to support provision of essential reproductive health
commodities, the World Bank through supporting pricing
and financing mechanisms, and UNICEF through its focus
on women and children and expertise in communication,
community mobilisation, and product procurement and
distribution.
• Develop appropriate strategies for product promotion,
delivery, and marketing, and for educating health profes-
sionals and potential consumers. Explore the best ways to
promote microbicides in the context of other prevention
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options and without undermining condom use. Conduct
further behavioural research to improve understanding of
protective behaviour in relationships, product preferences,
and acceptability of microbicides to women and men. 
• Build on the Global Campaign for STI/HIV Prevention
Alternatives, involving a wider range of organisations in
developing and developed countries in strategies to ensure
microbicide availability and access—for example, social 
marketing organisations, women’s groups, organisations
working on HIV/AIDS and on sexual and reproductive
health, development agencies, community organisations,
and the media. 
In 2000 the Rockefeller Foundation initiated a series of
consultations intended to identify ways to accelerate micro-
bicide research, development, and introduction. Dialogues
have been held with leading scientific institutions, advo-
cates, industry, donors, and other major stakeholder groups.
These discussions have identified specific challenges and pri-
orities facing the field, including insufficient capacity for
multiple large-scale clinical trials, limited manufacturing
capacity, regulatory uncertainty, and insufficient support 
for early stages of research on new compounds. The consul-
tative process will seek ways to overcome these problems
and explore new mechanisms to accelerate the development
process.
CONCLUSION
Microbicides offer a critically important new means to enable
women to protect themselves from HIV and other STIs with a
method under their control. By meeting this need and widen-
ing the choice of prevention options, microbicides have the
potential to exert a major impact on stemming the HIV/AIDS
epidemic. This urgent public health need is supported by
growing evidence and increasingly vocal demand for microbi-
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cides. Neglecting to make such products available would rep-
resent an international public health failure. 
There is broadening scientific consensus that microbicides
are feasible and a growing body of evidence about how best to
approach research and product development. Transforming
this promise into a safe, effective, and available product
requires a range of initiatives to accelerate the science and
increase investment. An urgent need is to provide proof of
concept to demonstrate that microbicides can be effective, and
advanced clinical trials to provide this evidence are of utmost
priority. 
The field faces a number of constraints, most notably
inadequate funding and lack of industry participation.
However, awareness of the potential of microbicides is
increasing in the donor community, and there are indications
that industry would be willing to play a more active role if
given evidence of effectiveness and appropriate incentives.
Much more can be done in this regard: developing a scientific
strategy and criteria for prioritising products through the R&D
process, especially effectiveness trials; brokering negotiations
among principal players from the public and private sectors;
and developing innovative partnerships to address concerns
about profitability and access. While an accelerated push must
be made on research and development, it is critical to begin
planning for product accessibility, introduction, and delivery.
These efforts can benefit from careful evaluation of similar
organizational initiatives created to stimulate research on vac-
cines and tropical diseases. 
Making microbicides available as rapidly as possible will
require accelerated scientific inquiry, global political commit-
ment, concerted efforts to raise awareness about the potential
of this approach, and a significant increase in investment from
public agencies, private foundations, individuals, and indus-
try. Targeting these resources efficiently will require close col-
laboration among scientists, researchers, technical agencies,
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donors, and advocates to create a strategic, product-oriented
development plan.
Women worldwide urgently need safe, effective, and
affordable microbicides to protect themselves from HIV and
STIs. A strategic research and development approach is critical
to achieving this fundamentally important goal. 
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“Microbicides offer a real possibility for helping women
protect themselves from HIV/AIDS and other STIs. 
We need to invest far more resources and energy if we are
to make this possibility a reality.”
Peter Piot
Executive Director, Joint United Nations
Programme on HIV/AIDS (UNAIDS)
“The development of safe, effective, and affordable 
microbicides is a priority for the European Commission.
I am, therefore, pleased to be able to offer my support to
The Case for Microbicides: A Global Priority. This document
will play an important role in increasing awareness
among policymakers of the potential of microbicides. 
It will also galvanise action to accelerate research and
development and help ensure future availability to those
most at risk in developing countries.”
Lieve Fransen
Development Directorate, European Commission 
